Last reviewed · How we verify
ALHEMO (CONCIZUMAB-MTCI)
ALHEMO (generic name: CONCIZUMAB-MTCI) is a drug developed by NOVO NORDISK INC. It is currently FDA-approved.
Concizumab, also known as ALHEMO, is an antibody that inhibits tissue factor pathway inhibitor. It is being studied for the treatment of Haemophilia A and Haemophilia B.
At a glance
| Generic name | CONCIZUMAB-MTCI |
|---|---|
| Sponsor | NOVO NORDISK INC |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Injection site reactions
- Headache
- Urticaria
Serious adverse events
- Renal infarct
- Hypersensitivity reaction
- Thromboembolic events
Key clinical trials
- Special Use-results Surveillance on Use of Alhemo in Patients With Haemophilia A or Haemophilia B Without Inhibitors A Multi-centre, Open-label, Non-interventional Post-marketing Study to Investigate (N/A)
- A Multi-centre, Open-label, Single-arm, Non-interventional Post-marketing Study to Investigate Safety and Clinical Parameters of Alhemo® Under Routine Clinical Practice in Japan (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALHEMO CI brief — competitive landscape report
- ALHEMO updates RSS · CI watch RSS
- NOVO NORDISK INC portfolio CI
Frequently asked questions about ALHEMO
What is ALHEMO?
ALHEMO (CONCIZUMAB-MTCI) is a pharmaceutical drug developed by NOVO NORDISK INC.
Who makes ALHEMO?
ALHEMO is developed and marketed by NOVO NORDISK INC (see full NOVO NORDISK INC pipeline at /company/novo-nordisk).
What is the generic name of ALHEMO?
CONCIZUMAB-MTCI is the generic (nonproprietary) name of ALHEMO.
What development phase is ALHEMO in?
ALHEMO is FDA-approved (marketed).
What are the side effects of ALHEMO?
Common side effects of ALHEMO include Injection site reactions, Headache, Urticaria. Serious adverse events: Renal infarct, Hypersensitivity reaction, Thromboembolic events.
Related
- Manufacturer: NOVO NORDISK INC — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing